Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

19310 items
2:09 AM, May 18, 2018  |  BioCentury | Emerging Company Profile

Accent on RNA

With its debut Friday with a $40 series A, Accent Therapeutics Inc. became the second disclosed newco to jump into the nascent arena of RNA epigenetics. The biotech has identified enzymes it believes drive cancer...
4:43 PM, May 15, 2018  |  BioCentury | Finance

Single Celsius

After identifying its first targets, Third Rock Ventures newco Celsius Therapeutics emerged from stealth with a $65 million series A round to apply single-cell genomics techniques to drug development for autoimmune diseases and cancer. GV,...
6:18 PM, May 11, 2018  |  BioCentury | Finance

HKEX opportunity knocking

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss. With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on April...
5:25 PM, May 11, 2018  |  BioCentury | Politics, Policy & Law

Getting reorganized

FDA is reorganizing the Office of New Drugs in its Center for Drug Evaluation and Research, seeking to make review oversight more consistent while encouraging senior staff to become thought leaders. The changes at OND...
4:17 PM, May 11, 2018  |  BioCentury | Finance

Aslan’s insiders

A disappointing offering on NASDAQ by Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) looks to be the consequence of Taiwan exchange rules that prevented more robust insider participation. So even though big names such as Morningside and...
3:55 PM, May 11, 2018  |  BioCentury | Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May 8,...
3:50 PM, May 11, 2018  |  BioCentury | Finance

Watching the wave

After raising the largest ever series B round for a Chinese biotech, CStone Pharmaceuticals Co. Ltd. should have enough funding to run four pivotal cancer studies in parallel as it monitors the performance of the...
2:33 PM, May 11, 2018  |  BioCentury | Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline. On...
1:39 PM, May 11, 2018  |  BioCentury | Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
12:19 PM, May 11, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least four profitable pharmas are slated to report earnings this week. (A) 12-month EPS; Source: Yahoo! Finance, Financial Times, company websites CompanyDatePre/post mkt1Q18 EPS est1Q17 EPSExpected chgTakeda Pharmaceutical Co. Ltd. (Tokyo:4502)5/14PostNA¥146.26 (A)NAEisai Co....

Pages